{"Clinical Trial ID": "NCT00513292", "Intervention": ["INTERVENTION 1:", "FEC-75 and then Paclitaxel/Trastuzumab", "Patients receive fluorouracil, epirubicin and cyclophosphamide (FEC) including fluorouracil IV, epirubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment is repeated every 21 days for 4 courses. From 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients are operated. From 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for 52 weeks.", "INTERVENTION 2:", "- Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75", "Patients receive paclitaxel IV once a week and trastuzumab IV once a week for 12 weeks. From 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC containing fluoruracil IV, epirubin IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once a week for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery."], "Eligibility": ["Incorporation criteria:", "Diagnosis of invasive adenocarcinoma by heart needle biopsy", "A fine needle aspiration is permitted provided that the primary tumour < 2 cm and the metastases of the lymph nodes are present.", "A biopsy excision of the authorised primary tumour provided that the biopsy-positive lymph nodes are present", "Primary tumour 2 cm and/or 1 lymph node positive for biopsy", "HER2-positive disease", "In-situ fluorescent hybridization (FISH) confirmation requires gene amplification", "Immunohistochemical confirmation (IHC) requires a strongly positive (3+) colouring intensity score", "In situ ductal carcinoma (CDIS) or contralateral breast synchronous DCIS, regardless of the previously authorised treatment", "Invasive synchronous breast cancer is not allowed", "Ipsilateral IDIS treated with local excision with or without authorised hormonal treatment", "People treated with radiation therapy are not allowed", "No definitive clinical or radiological evidence of metastatic disease", "No history of invasive breast cancer", "Known situation of hormone receptors", "\u2022 Menopausal status not specified", "State of ECOG performance from 0 to 1", "Absolute number of neutrophils 1,200/mm3", "Number of platelets 100 000/mm3", "Unless the patient has a Grade 1 bilirubin elevation (normal at 1.5 times the upper limit of normal [ULN]) resulting from Gilbert's disease or similar syndrome due to slow conjugation of bilirubin", "- Alkaline phosphatase 2.5 times ULN", "AST 1.5 times ULN", "Normal creatinine", "The left ventricular ejection fraction (LVEF) 55 by multi-door acquisition scanning (MUGA) or echocardiogram (ECHO) in the last 3 months", "Patients with skeletal pain or alkaline phosphatase > ULN but allowed 2.5 ULN if bone scans do not demonstrate metastatic disease", "- Suspicious observations on bone analysis should be confirmed as benign by X-ray, MRI or biopsy.", "\u2022 Previous non-brain malignancies are allowed if they have been disease free for 5 years since the completion of the initial treatment and if their doctor believes they are at low risk of recidivism.", "Patients with the following cancers are eligible if they are diagnosed and treated in the last 5 years:", "In situ carcinoma of the cervix", "Colon carcinoma in situ", "In situ melanoma", "Basal cell and squamous skin carcinoma", "No cardiac disease that would prevent the use of epirubin hydrochloride or trastuzumab (Herceptin\u00ae), including any of the following:", "\u2022 Active heart disease", "Angina pectoris which requires the use of anti-anginal medicines", "Cardiac arrhythmia requiring medication", "\u2022 Severe abnormality of conduction", "Clinically significant valvular disease", "Cardiomegaly on chest x-ray", "- Ventricular hypertrophy on EKG", "Patients with poorly controlled hypertension (i.e. diastolic greater than 100 mm/Hg)", "Patients with high blood pressure who are well controlled by medicines are eligible.", "\u2022 History of heart disease", "A myocardial infarction documented as a clinical diagnosis or by EKG or any other test", "Documented congestive heart failure", "Documented cardiomyopathy", "No sensory neuropathy or motor of grade 2, as defined by the NCI CTCAE v3.0", "Women with reproductive potential should agree to use an effective non-hormonal contraceptive method during treatment.", "Women of childbearing potential must undergo a negative urine or serum pregnancy test within 2 weeks of registration.", "No pregnancy or breast-feeding", "There is no psychiatric or addictive disorder or other condition that, in the opinion of the investigator, would prevent the patient from meeting the requirements of the study.", "No non-malignant systemic disease (e.g., cardiovascular, renal, hepatic) that would prevent treatment with any of the treatments", "No prior axillary surgery", "A prior non-excision biopsy of an axillary node is permitted", "No prior treatment for breast cancer", "A hormone treatment is allowed if it has been administered for a total of 28 days at any time after diagnosis and before entry into the study.", "The hormone treatment should stop at or before the time of entry into the study and be resumed, if necessary, after surgery.", "No previous treatment with anthracyclines or taxanes for any malignancy", "No other research officer in the last 30 days", "No concomitant sexual hormonal therapy (e.g. contraceptive pills, ovarian hormone replacement therapy)", "No concomitant treatment with a hormonal agent such as raloxifene, tamoxifen or other selective estrogen receptor modulator (SERM), either for osteoporosis or for the prevention of breast cancer"], "Results": ["Performance measures:", "PCR inside the breast, defined as no evidence of invasive tumours in the breast at surgery after completion of chemotherapy", "In the final analysis for the publication, the rates will be based on the blind central examination of these institutional pathology reports. The Chi-square test will be performed at both sides 0.05. A 95% confidence interval will be calculated for the difference in SPC rates.", "Time limit: up to 5 years", "Results 1:", "Title of arm/group: FEC-75 and then Paclitaxel/Trastuzumab", "Patients receive fluorouracil, epirubicin and cyclophosphamide (FEC) including fluorouracil IV, epirubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment is repeated every 21 days for 4 courses. From 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients are operated. From 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for 52 weeks.", "Total number of participants analysed: 138", "Type of measurement: Number", "Unit of measure: percentage of participants 56.5 (47.8 to 64.9)", "Results 2:", "Title of arm/group: Paclitaxel/Trastuzumab and Trastuzumab/FEC-75", "Patients receive paclitaxel IV once a week and trastuzumab IV once a week for 12 weeks. From 7 days after completion of paclitaxel and trastuzumab, patients receive FEC including fluorouracil IV, epirubin IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once a week for 12 additional weeks. Within 6 weeks after completion of FEC and trastuzumab, patients are operated.", "Total number of participants analysed: 142", "Type of measurement: Number", "Unit of measure: percentage of participants 54.2 (45.7 to 62.6)"], "Adverse Events": ["Undesirable Events 1:", "Total: 19/138 (13.77%)", "Haematological disorders 1/138 (0.72%)", "- Febrile neutropenia 1/138 (0.72 %)", "Haemoglobin reduction 8/138 (5.80 %)", "Haemolysis 0/138 (0.00 %)", "Atrial fibrillation 0/138 (0.00 %)", "- Left ventricular defect 3/138 (2.17 per cent)", "Ischemic myocardium 0/138 (0.00 %)", "Sinus tachycardia 1/138 (0.72%)", "- Superventricular tachycardia 0/138 (0.00 %)", "- Extraocular muscle paresis 0/138 (0.00 %)", "Adverse Events 2:", "Total: 26/142 (18.31 per cent)", "Haematological disorders 1/142 (0.7%)", "Febrile neutropenia 3/142 (2.11 per cent)", "Haemoglobin decrease 11/142 (7.75%)", "Haemolysis 1/142 (0.70 per cent)", "Atrial fibrillation 1/142 (0.70 %)", "- Left ventricular defect 5/142 (3.52%)", "Ischemia myocardial 1/142 (0.70 per cent)", "Sinus tachycardia 1/142 (0.70 %)", "- Superventricular tachycardia 1/142 (0.70 %)", "- Extraocular muscle paresis 1/142 (0.7%)"]}